• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - Product Image

Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  • Published: January 2012
  • Region: Global
  • 75 Pages
  • GlobalData

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Pfizer Inc.
  • Sanofi
  • MORE

Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Venous Thromboembolism Therapeutics market. The report identifies the key trends shaping and driving the global Venous Thromboembolism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Venous Thromboembolism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Venous Thromboembolism Therapeutics market. Its scope includes -
- READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Venous Thromboembolism (VTE) Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Risk Factors
2.5 Clinical Presentation / Symptoms
2.5.1 Deep Venous Thrombosis (DVT)
2.5.2 Pulmonary Embolism (PE)
2.6 Diagnosis
2.6.1 Deep Venous Thrombosis (DVT)
2.6.2 Pulmonary Embolism (PE)
2.7 Pathophysiology
2.7.1 Deep Venous Thrombosis (DVT)
2.7.2 Pulmonary Embolism (PE)
2.8 Treatment
2.8.1 Deep Venous Thrombosis (DVT)
2.8.2 Pulmonary Embolism (PE)
2.9 Other Procedures and Devices for VTE
2.9.1 Pulmonary Embolectomy
2.9.2 Vena Caval Interruption
2.9.3 Compression Stockings
2.10 GlobalData Pipeline Report Guidance
3 VTE Therapeutics - Market Characterization
3.1 Overview
3.2 VTE Therapeutics Market Size (2005-2010) - Global
3.3 VTE Therapeutics Market Forecast (2010-2018) - Global
3.4 VTE Therapeutics Market Size (2005-2010) - The US
3.5 VTE Therapeutics Market Forecast (2010-2018) - The US
3.6 VTE Therapeutics Market Size (2005-2010) - France
3.7 VTE Therapeutics Market Forecast (2010-2018) - France
3.8 VTE Therapeutics Market Size (2005-2010) - Germany
3.9 VTE Therapeutics Market Forecast (2010-2018) - Germany
3.10 VTE Therapeutics Market Size (2005-2010) - Italy
3.11 VTE Therapeutics Market Forecast (2010-2018) - Italy
3.12 VTE Therapeutics Market Size (2005-2010) - Spain
3.13 VTE Therapeutics Market Forecast (2010-2018) - Spain
3.14 VTE Therapeutics Market Size (2005 2010) - The UK
3.15 VTE Therapeutics Market Forecast (2010-2018) - The UK
3.16 VTE Therapeutics Market Size (2005 2010) - Japan
3.17 VTE Therapeutics Market Forecast (2010 2018) - Japan
3.18 Drivers and Barriers for the VTE Therapeutics Market
3.18.1 Drivers for the VTE Therapeutics Market
3.18.2 Barriers for the VTE Therapeutics Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 VTE Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the VTE Therapeutics Market - Heparin Class
4.3.1 Enoxaparin
4.3.2 Dalteparin
4.3.3 Warfarin
4.3.4 Xarelto
4.3.5 Fondaparinux
4.3.6 Apixaban (Eliquis)
4.4 Key Takeaway
5 VTE Therapeutics Market - Pipeline Assessment
5.1 Overview
5.1.1 VTE Therapeutics - Phase III Clinical Pipeline
5.1.2 VTE Therapeutics - Phase II Clinical Pipeline
5.1.3 VTE Therapeutics - Phase I Clinical Pipeline
5.1.4 VTE Therapeutics - Preclinical and Discovery Clinical Pipeline
5.2 VTE Therapeutics Market - Pipeline Assessment by Mechanism of Action
5.3 VTE Therapeutics Market - Technology Trends Analytical Framework
5.4 VTE Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
5.5 VTE Therapeutics - Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Edoxaban (DU-176b)
5.7 Key Takeaway
6 VTE Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent and Overall Sponsors
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials
7 VTE Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 VTE Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Boehringer Ingelheim GmbH
8.2.2 Bristol-Myers Squibb
8.2.3 Daiichi Sankyo
8.2.4 Pfizer Inc.
8.2.5 Sanofi
9 VTE Therapeutics - Acquisition Deals
10 VTE Therapeutics Market - Appendix
10.1 Market Definition
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: VTE Therapeutics Market, Global, Revenues ($m), 2005 2010
Table 2: VTE Therapeutics Market, Global, Market Forecasts ($m), 2010 2018
Table 3: VTE Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 4: VTE Therapeutics Market, The US, Market Forecasts ($m), 2010-2018
Table 5: VTE Therapeutics Market, France, Revenue ($m), 2005-2010
Table 6: VTE Therapeutics Market, France, Market Forecast ($m), 2010-2018
Table 7: VTE Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 8: VTE Therapeutics Market, Germany, Market Forecast ($m), 2010-2018
Table 9: VTE Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 10: VTE Therapeutics Market, Italy, Market Forecast ($m), 2010-2018
Table 11: VTE Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 12: VTE Therapeutics Market, Spain, Market Forecast ($m), 2010-2018
Table 13: VTE Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 14: VTE Therapeutics Market, The UK, Market Forecast ($m), 2010-2018
Table 15: VTE Market, Japan, Revenue ($m), 2005-2010
Table 16: VTE Therapeutics Market, Japan, Market Forecast ($m), 2010-2018
Table 17: Major Marketed Products Comparison in the VTE Therapeutics Market, 2011
Table 18: VTE Therapeutics Market - Phase III Clinical Pipeline, 2011
Table 19: VTE Therapeutics Market - Phase II Clinical Pipeline, 2011
Table 20: VTE Therapeutics Market - Phase I Clinical Pipeline, 2011
Table 21: VTE Therapeutics Market - Preclinical Pipeline, 2011
Table 22: VTE Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 23: VTE Market, Global, Clinical Trials by Country, 2011
Table 24: VTE Market, Global, Clinical Trials by Phase, 2011
Table 25: VTE Market, Global, Clinical Trials by Status of Development, 2011
Table 26: VTE Market, Global, Sponsors, 2011
Table 27: VTE Market, Global, Companies by Phase, 2011
Table 28: VTE Therapeutics, Global, Deals, 2011

1.2 List of Figures
Figure 1: DVT: Risk Factors
Figure 2: DVT: Clinical Presentation
Figure 3: PE: Clinical Presentation
Figure 4: VTE Therapeutics Market, Global, Revenues ($m), 2005 2010
Figure 5: VTE Therapeutics Market, Global, Market Forecast ($m), 2010 2018
Figure 6: VTE Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 7: VTE Therapeutics Market, The US, Market Forecasts ($m), 2010-2018
Figure 8: VTE Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 9: VTE Therapeutics Market, France, Market Forecast ($m), 2010-2018
Figure 10: VTE Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 11: VTE Therapeutics Market, Germany, Market Forecast ($m), 2010-2018
Figure 12: VTE Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 13: VTE Therapeutics Market, Italy, Market Forecast ($m), 2010-2018
Figure 14: VTE Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 15: VTE Therapeutics Market, Spain, Market Forecast ($m), 2010-2018
Figure 16: VTE Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 17: VTE Therapeutics Market, The UK, Market Forecast ($m), 2010-2018
Figure 18: VTE Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 19: VTE Therapeutics Market, Japan, Market Forecast ($m), 2010-2018
Figure 20: Opportunity and Unmet Need in the VTE Therapeutics Market
Figure 21: Strategic Competitor Assessment of the Marketed Products for VTE, 2011
Figure 22: VTE Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 23: Technology Trends Analytic Framework of the VTE Pipeline, 2011
Figure 24: Technology Trends Analytic Framework of the VTE Pipeline - Description, 2011
Figure 25: VTE Pipeline by Phase of Clinical Development, 2011
Figure 26: VTE Market, Global, Clinical Trials by Country, 2011
Figure 27: VTE Market, Global, Clinical Trials by Phase, 2011
Figure 28: VTE Market, Global, Clinical Trials by Stage of Development, 2011
Figure 29: VTE Market, Global, Prominent Sponsors, 2011
Figure 30: VTE Market, Global, Overall Sponsors, 2011
Figure 31: VTE, Market, Global, Companies by Phase, 2011
Figure 32: VTE Market, Drivers and Barriers, 2011
Figure 33: Implications for Future Market Competition in the VTE Therapeutics Market, 2011
Figure 34: VTE Therapeutics Market - Clinical Pipeline by Company, 2011
Figure 35: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global VTE market. The report identifies the key trends shaping and driving the global VTE market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global VTE sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The VTE Therapeutics Market is Forecast to Show Significant Growth Until 2018

GlobalData’s analysis suggests that the global VTE therapeutics market was worth $2.9 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% for the next eight years, to reach $5.1 billion by 2018. The global VTE therapeutics market is being driven by the launch of new and efficacious treatment options and an increasing incidence rate. The growth will be further augmented by the increasing uptake of oral factor Xa inhibitor in treatment, and advancements in efficient and accurate diagnostic tools and techniques. For past many years, warfarin, vitamin K antagonists supplied as Coumadin by Bristol-Myers Squibb's and generics was the only oral anticoagulants available. But limitation with such oral anticoagulant (OAC) drug is they require dose modification based on patient monitoring. The OAC that are expected to launch in near future will offer significant advantages over currently available OAC drug. Most notably, Bayer Xarelto (rivaroxaban), Bristol-Myers Squibb/Pfizer's apixaban (Eliquis) and Boehringer Ingelheim's Pradaxa (dabigatran etexilate) will not require patient monitoring or dose adjustment.

Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Daiichi Sankyo
Pfizer Inc.
Sanofi

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos